¼¼°èÀÇ ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå
Multiple Myeloma Drugs
»óǰÄÚµå : 1794502
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀº 2030³â±îÁö 286¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 212¾ï ´Þ·¯·Î ÃßÁ¤µÈ ¼¼°èÀÇ ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 5.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 286¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠǥÀûÄ¡·á´Â CAGR 4.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 110¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ý¹°ÇÐÀû ¿ä¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 58¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 58¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 8.0%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð°¡ 56¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.6%¿Í 5.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ °³¹ßÀÌ ºü¸£°Ô ÁøÇàµÇ´Â ÀÌÀ¯

´Ù¹ß¼º°ñ¼öÁ¾Àº º¹ÀâÇÑ º´ÅÂ¿Í Àç¹ß¼ºÀ¸·Î ÀÎÇØ ¿©ÀüÈ÷ °¡Àå Ȱ¹ßÇÏ°Ô ¿¬±¸µÇ°í ÀÖ´Â Ç÷¾×¾Ï Áß ÇϳªÀÔ´Ï´Ù. ´Ù¹ß¼º°ñ¼öÁ¾Àº ´ëºÎºÐÀÇ °æ¿ì ºÒÄ¡º´ÀÌÁö¸¸, ¾à¹° °³¹ßÀÇ ¹ßÀüÀ¸·Î Áúº´ °ü¸®¿Í ȯÀÚ »ýÁ¸À²ÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ÇöÀç´Â ¸é¿ªÁ¶ÀýÁ¦, ÇÁ·ÎÅ×¾ÆÁ» ¾ïÁ¦Á¦, ¸ð³ëŬ·Î³Î Ç×ü, ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀÌµå µîÀ» º´¿ëÇÏ´Â Ä¡·á¹ýÀÌ ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¶ÇÕÀº µµÀÔ ¿ä¹ý, À¯Áö ¿ä¹ý, Àç¹ß Ä¡·á ¿ä¹ýÀÇ °ñ°ÝÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ¾àÁ¦±ºº° ¹× Ç¥Àû Ä¡·á´Â ½Å±Ô Áø´Ü ȯÀÚ ¹× ³­Ä¡¼º ȯÀÚ ¸ðµÎ¿¡ ´ëÇÑ Ä¡·áÀÇ Àü¸ÁÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù.

Ä¡·á ¸ñÇ¥´Â °üÇØ È®´ë, Àç¹ß Áö¿¬, Á¤È®ÇÑ ºÎÀÛ¿ë °ü¸® µîÀÔ´Ï´Ù. À¯ÀüÀÚ ¸¶Ä¿, ¼¼Æ÷À¯ÀüÇÐÀû À§Çèµµ, Ä¡·á Àü È¿°ú¿¡ ±â¹ÝÇÑ °³º°È­ ¿ä¹ýÀÌ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. 3Á¦ º´¿ë¿ä¹ý, 4Á¦ º´¿ë¿ä¹ý, Àû°Ý ȯÀÚ¿¡°Ô Áٱ⼼Æ÷ À̽ÄÀ» »ç¿ëÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀº µ¶¼ºÀ» ÃÖ¼ÒÈ­Çϸ鼭 Áö¼ÓÀûÀÎ ¹ÝÀÀÀ» ¾ò±â À§ÇÑ ÁøÈ­ÇÑ ÀÓ»ó Àü·«À» ¹Ý¿µÇÕ´Ï´Ù. ´Ù¹ß¼º°ñ¼öÁ¾Àº ¸Å¿ì ºÒ±ÕÀÏÇϹǷΠġ·á¹ý ¼±ÅÃÀº Á¡Á¡ ´õ ȯÀÚº° Áúº´ Ư¼º°ú ³»¾à¼º ÇÁ·ÎÆÄÀÏÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

Â÷¼¼´ë ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·á´Â ¾î¶² Çõ½ÅÀ¸·Î Çü¼ºµÇ°í Àִ°¡?

ÃÖ±Ù Çõ½Å ±â¼ú·Î´Â CD38, SLAMF7°ú °°Àº Ç¥¸é Ç׿øÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ´ÜŬ·Ð Ç×ü¸¦ µµÀÔÇÏ¿© °ñ¼öÁ¾ ¼¼Æ÷ÀÇ ¸é¿ª ¸Å°³¼º »ç¸êÀ» °­È­ÇÏ´Â °ÍÀÌ ÀÖ½À´Ï´Ù. ÀÌ ¾àÁ¦µéÀº Á¾Á¾ ±âÁ¸ Ä¡·á¹ý°ú º´¿ëÇÏ¿© ¹«ÁøÇà»ýÁ¸±â°£¿¡ À¯ÀǹÌÇÑ °³¼±À» º¸¿´À¸¸ç, ¹«ÁøÇà»ýÁ¸±â°£µµ À¯ÀÇÇÏ°Ô °³¼±µÇ¾ú½À´Ï´Ù. ÀÌÁ߯¯ÀÌÀû T¼¼Æ÷À¯ÀüÀÚ(BiTE)¿Í Ç×ü-¾à¹° Á¢ÇÕü(ADC)µµ ¸é¿ª¹ÝÀÀÀ» ÀÌ¿ëÇϸ鼭 Á¾¾ç¼¼Æ÷¿¡ Á÷Á¢ °ü¿©ÇÏ´Â ´É·Â¿¡ ´ëÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

CAR T ¼¼Æ÷ Ä¡·á¿Í °°Àº ¼¼Æ÷ ±â¹Ý Ä¡·á´Â ÁßÁõ ÀüÄ¡ ¹× Àç¹ß ȯÀÚµéÀ» À§ÇÑ ÁÖ¿ä °ü½É ºÐ¾ß°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀº °ñ¼öÁ¾ ƯÀÌ Ç׿øÀ» Ç¥ÀûÀ¸·Î Çϴ ȯÀÚ ÀÚ½ÅÀÇ T¼¼Æ÷¸¦ °øÇÐÀûÀ¸·Î ¸¸µé¾î³»´Â Ä¡·á¹ýÀÔ´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè¿¡¼­ Ä¡·á Ãʱ⠴ܰèÀÇ °¡´É¼ºÀ» Æò°¡Çϰí ÀÖÀ¸¸ç, ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè¿¡¼­´Â ÁøÇ༺ Áúȯ¿¡¸¸ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. °æ±¸¿ë ÇÁ·ÎÅ×¾ÆÁ» ¾ïÁ¦Á¦ ¹× 2¼¼´ë ¸é¿ªÁ¶ÀýÁ¦´Â ƯÈ÷ Àå±â À¯Áö¿ä¹ý¿¡¼­ ÆíÀǼº Çâ»ó°ú ºÎÀÛ¿ë °¨¼Ò¸¦ ¸ñÇ¥·Î °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

¼ö¿ä¸¦ ÁÖµµÇϴ ȯÀÚ ºÎ¹®°ú ÇコÄɾî ȯ°æÀº?

Àç¹ß ¹× ³­Ä¡¼º ȯÀÚ´Â °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â Ä¡·á ºÐ¾ß·Î »õ·Î¿î ÀÛ¿ë±âÀüÀ» °¡Áø »õ·Î¿î ¾à¹°ÀÌ ÇÊ¿äÇÑ ºÐ¾ßÀÔ´Ï´Ù. °í·ÉÀÇ È¯ÀÚ³ª ÇÕº´ÁõÀÌ Àִ ȯÀÚµéÀº ´õ ³·Àº °­µµÀÇ ¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â °æ¿ì°¡ ¸¹¾Æ º´¿ø ¹Û¿¡¼­ Åõ¿©ÇÒ ¼ö ÀÖ´Â °æ±¸Á¦³ª ÇÇÇÏÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ¿Ü·¡ ¼ö¾× ¼¾ÅÍ, Àü¹® ¾à±¹, ÀçÅÃÄ¡·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ƯÈ÷ Ä¡·á ±â°£ÀÌ ¼ö°³¿ù¿¡¼­ ¼ö³âÀ¸·Î ´Ã¾î³²¿¡ µû¶ó Ä¡·á Á¦°ø¿¡ ´õ ¸¹ÀÌ °ü¿©Çϰí ÀÖ½À´Ï´Ù.

Áø´ÜÀÇ °³¼±À¸·Î Á¶±â ¹ß°ß°ú À§Çèµµ ºÐ·ù°¡ °¡´ÉÇØÁ® °íÀ§Ç豺 ȯÀڵ鿡 ´ëÇÑ Á¶±â °³ÀÔÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. °ñÁúȯ, ½ÅÀå ±â´É Àå¾Ö, Ä¡·á °ü·Ã ºÎÀÛ¿ëÀ» °ü¸®Çϱâ À§ÇÑ ÁöÁö¿ä¹ýµµ °³¼±µÇ¾î º´¿ë ¿ä¹ý¿¡ ´ëÇÑ Æø³ÐÀº Á¢±ÙÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÁöºÒÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â °¡Ä¡ ±â¹Ý Ä¡·á¸¦ Áß½ÃÇϰí, Çã¿ë °¡´ÉÇÑ µ¶¼º ÇÁ·ÎÆÄÀÏ·Î Àå±âÀûÀÎ Áúº´ ÅëÁ¦¸¦ º¸¿©ÁÖ´Â Ä¡·á¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â Àü ¼¼°è Æ÷¹Ä·¯¸®¿¡ ´ëÇÑ ÅëÇÕ ¹× ȯÀÚ Á¢±Ù Àü·«¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù.

´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è À¯º´·ü Áõ°¡, ƯÈ÷ °í·ÉÈ­ »çȸÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ Ä¡·á ´ë»óÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¸é¿ªÄ¡·áÁ¦, ¼¼Æ÷Ä¡·áÁ¦, Ç¥ÀûÄ¡·áÁ¦ÀÇ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀÌ ÀÓ»ó µµÀÔ°ú ÀûÀÀÁõ È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Áø´Ü Á¤È®µµÀÇ Çâ»óÀ¸·Î À§Çè¿¡ ¸Â´Â Ä¡·á °èȹÀ» ¼¼¿ï ¼ö ÀÖ°Ô µÇ¸é¼­ 1Â÷ Ä¡·á¿Í ±¸Á¦ Ä¡·á ¸ðµÎ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿Ü·¡ Ä¡·á¿Í ÀçÅà ġ·á·ÎÀÇ ÀüȯÀ¸·Î °æ±¸Á¦ ¹× ÇÇÇÏÁÖ»çÁ¦ »ç¿ëÀÌ Áõ°¡Çß½À´Ï´Ù. º´¿ë¿ä¹ý ¹× À¯Áö¿ä¹ýÀÌ ¹Þ¾Æµé¿©Áö°í, Ä¡·á ±â°£ÀÌ ¿¬ÀåµÇ¸ç, ¼ö¿ä°¡ Áö¼ÓµË´Ï´Ù. ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷ÀÇ ÆÄÀÌÇÁ¶óÀÎ °³¹ß ¹× ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ·Î Áö¿ª °£ ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÊ.

ºÎ¹®

Ä¡·á¹ý(Ç¥ÀûÄ¡·á, »ý¹°ÇÐÀû ¿ä¹ý, È­Çпä¹ý, ±âŸ Ä¡·á¹ý), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Multiple Myeloma Drugs Market to Reach US$28.6 Billion by 2030

The global market for Multiple Myeloma Drugs estimated at US$21.2 Billion in the year 2024, is expected to reach US$28.6 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Biologic Therapy segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 8.0% CAGR

The Multiple Myeloma Drugs market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Multiple Myeloma Drugs Market - Key Trends & Drivers Summarized

Why Is Drug Development for Multiple Myeloma Advancing Rapidly?

Multiple myeloma remains one of the most actively researched hematologic cancers due to its complex pathology and recurring nature. While it remains incurable in most cases, advances in drug development have led to significant improvements in disease management and patient survival. Therapeutic approaches now combine immunomodulators, proteasome inhibitors, monoclonal antibodies, and corticosteroids. These combinations form the backbone of induction, maintenance, and relapsed therapy regimens. New drug classes and targeted therapies are expanding the treatment landscape for both newly diagnosed and refractory patients.

Treatment goals include deepening remission, delaying relapse, and managing side effects with improved precision. Personalized regimens are becoming common, based on genetic markers, cytogenetic risk, and prior response. The growing use of triplet and quadruplet regimens, as well as stem cell transplantation in eligible patients, reflects an evolving clinical strategy that seeks durable responses while minimizing toxicity. As multiple myeloma is highly heterogeneous, therapeutic choices increasingly reflect patient-specific disease characteristics and tolerance profiles.

What Innovations Are Shaping the Next Generation of Multiple Myeloma Therapies?

Recent innovations include the introduction of monoclonal antibodies targeting surface antigens such as CD38 and SLAMF7, which enhance immune-mediated killing of myeloma cells. These agents, often combined with established therapies, have shown meaningful improvements in progression-free survival. Bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs) are also being studied for their ability to directly engage tumor cells while harnessing immune response.

Cell-based therapies such as CAR T-cell treatments have become a major area of interest for heavily pretreated or relapsed patients. These therapies involve engineering a patient’s own T-cells to target myeloma-specific antigens. Though currently reserved for advanced cases, ongoing trials are assessing their potential earlier in the treatment sequence. Oral proteasome inhibitors and second-generation immunomodulators are being developed to improve convenience and reduce adverse effects, especially in long-term maintenance settings.

Which Patient Segments and Healthcare Settings Are Driving Demand?

Relapsed and refractory patients represent the fastest-growing treatment segment, requiring novel agents with new mechanisms of action. Elderly patients and those with comorbidities often require lower-intensity regimens, creating demand for oral or subcutaneous formulations that can be administered outside of hospital settings. Outpatient infusion centers, specialty pharmacies, and home healthcare providers are increasingly involved in care delivery, especially as treatment durations extend over months or years.

Diagnostic improvements are enabling earlier identification and risk stratification, leading to earlier intervention in high-risk patients. Supportive care for managing bone disease, renal dysfunction, and treatment-related side effects is also improving, allowing broader access to combination regimens. Payers and providers are emphasizing value-based care, focusing on therapies that demonstrate long-term disease control with acceptable toxicity profiles. This shift is influencing formulary inclusion and patient access strategies worldwide.

Growth in the Multiple Myeloma Drugs Market Is Driven by Several Factors…

Growth in the multiple myeloma drugs market is driven by several factors. Rising global incidence, particularly in aging populations, is expanding the treatment pool. Continuous innovation in immunotherapies, cell therapies, and targeted agents supports clinical adoption and label expansion. Improved diagnostic precision allows for risk-adapted treatment planning, increasing demand for both frontline and salvage therapies. Shift toward outpatient and home-based treatment delivery boosts use of oral and subcutaneous agents. Growing acceptance of combination regimens and maintenance therapy extends duration of treatment, generating sustained demand. Investment by biopharmaceutical companies in pipeline development and clinical trials further accelerates market expansion across regions.

SCOPE OF STUDY:

The report analyzes the Multiple Myeloma Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â